Skip to content

CYCLO THERAPEUTICS, INC.: 10-Q filed 2016-08-12

What CYCLO THERAPEUTICS, INC. reported in its quarterly report filed 2016-08-12 (fiscal Q2 2016): 26 published measures, 67 facts as tagged in accession 0001213900-16-015841.

This filing

Form
10-Q (quarterly report)
Filed
2016-08-12
Fiscal period
fiscal Q2 2016
Accession
0001213900-16-015841 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CYCLO THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2016-06-304,971,657USD
At 2015-12-314,757,253USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2016-06-303,848,751USD
At 2015-12-313,745,683USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2016-06-302,133,725USD
At 2015-12-311,842,233USD
At 2015-06-301,426,589USD
At 2014-12-312,380,054USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2016-04-01 to 2016-06-30-1,071,161USD91
2016-01-01 to 2016-06-30-1,776,932USD182
2015-01-01 to 2015-12-312,551,000USD365
2015-04-01 to 2015-06-30-360,180USD91
2015-01-01 to 2015-06-30-748,436USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2016-01-01 to 2016-06-30-1,530,291USD182
2015-01-01 to 2015-12-311,989,000USD365
2015-01-01 to 2015-06-30-699,428USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2016-01-01 to 2016-06-309,343USD182
2015-01-01 to 2015-06-30225,175USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2016-01-01 to 2016-06-301,814,701USD182
2015-01-01 to 2015-06-30-29,562USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2016-01-01 to 2016-06-307,082USD182
2015-01-01 to 2015-06-30-224,475USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2016-06-30-7,052,698USD
At 2015-12-31-5,275,766USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2016-06-301,810,054USD
At 2015-12-311,892,943USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2016-04-01 to 2016-06-30-1,067,428USD91
2016-01-01 to 2016-06-30-1,767,022USD182
2015-04-01 to 2015-06-30-352,361USD91
2015-01-01 to 2015-06-30-734,898USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2016-06-302,869,404USD
At 2015-12-312,522,886USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2016-04-01 to 2016-06-307,173USD91
2016-01-01 to 2016-06-3014,753USD182
2015-04-01 to 2015-06-307,899USD91
2015-01-01 to 2015-06-3015,778USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2016-06-301,122,906USD
At 2015-12-311,011,570USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2016-06-3081,150USD
At 2015-12-3155,636USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2016-06-30616,562USD
At 2015-12-31610,166USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2016-04-01 to 2016-06-30660,867USD91
2016-01-01 to 2016-06-30943,549USD182
2015-04-01 to 2015-06-30110,834USD91
2015-01-01 to 2015-06-30178,065USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2016-06-3066,670,347shares
At 2015-12-3158,670,347shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2016-06-3010,894,782USD
At 2015-12-319,015,582USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2016-06-30704,275USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2016-06-30292,199USD
At 2015-12-31341,424USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2016-04-01 to 2016-06-30-1,071,161USD91
2016-01-01 to 2016-06-30-1,776,932USD182
2015-04-01 to 2015-06-30-360,180USD91
2015-01-01 to 2015-06-30-748,436USD181

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2016-01-01 to 2016-06-3088,357USD182
2015-01-01 to 2015-06-3080,564USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2016-04-01 to 2016-06-30-3,733USD91
2016-01-01 to 2016-06-30-9,910USD182
2015-04-01 to 2015-06-30-7,819USD91
2015-01-01 to 2015-06-30-13,538USD181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2016-01-01 to 2016-06-3025,514USD182
2015-01-01 to 2015-06-30-31,684USD181

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2016-01-01 to 2016-06-301,438USD182
2015-01-01 to 2015-06-3026,877USD181

Inspect the source

Entity
CYCLO THERAPEUTICS, INC. / CIK 0000922247
Captured
2026-09-21T17:17:43.874Z
SEC response SHA-256
00eb7fd40e8240f18174ace9c17e250765347f97ee2730b0222250298ac67de3

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000922247.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))